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REVIEW ARTICLE
Contributing role of extracellular vesicles on vascular
endothelium haemostatic balance in cancer
Ce´line Bouvy1*, Damien Gheldof2, Christian Chatelain2, Franc¸ois Mullier2$
and Jean-Michel Dogne´1$
1Department of Pharmacy, Namur Research Institute of Life Sciences (NARILIS), Namur Thrombosis
and Hemostasis Center (NTHC), University of Namur, Namur, Belgium; 2Department of Hematology,
Namur Thrombosis and Hemostasis Center (NTHC), CHU Dinant-Godinne, UCL Namur, Yvoir, Belgium
Extracellular vesicles (EVs) generated during tumourigenesis are thought to play a major role in the hyper-
coagulant state observed in cancer patients. They exhibit negatively charged phospholipids and tissue factor
(TF) that promote coagulation cascade activation. In addition, they contain surface proteins and cytoplasmic
molecules, both originating from the producing cell that can impact target cells’ expression. By targeting
endothelial cells of blood vessels, these EVs could disturb the physiological anticoagulant properties of these
cells and be partly responsible for the vascular endothelium activation observed in cancer patients. Indeed,
vascular endothelium naturally exhibits heparin-like proteoglycan, TF pathway inhibitor and protein C
anticoagulant pathway that prevent thrombosis in physiological condition. An overexpression of TF and a
decreased expression of coagulation cascade inhibitors have been reported after EVs’ treatment of endothelial
cells. The induction of apoptosis and an increased expression of platelet adhesion molecules have also been
highlighted. These events may promote thrombus formation in cancer. The aim of this paper is to provide a
targeted review on the current evidence and knowledge of roles and impact of EVs on endothelial surface
anticoagulant and procoagulant factors and cellular adhesion molecules expression.
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T
he relationship between cancer and thrombosis
began with Trousseau’s researches in 1865. Cur-
rently, thrombosis is the second leading cause of
death in cancer patients after malignancy itself (1). The
overall procoagulant state leading to thrombosis is vari-
able depending on cancer type, stage and treatment. A
total of 1829% of patients diagnosed with thromboem-
bolism actually suffer from cancer (2). The underlying
pathophysiological mechanism of thrombotic events in
cancer patients is multifactorial. Among the contributing
factors, extracellular vesicles (EVs) produced by tumour
cells and their microenvironment generate considerable
interest since the discovery of their pro- and anticoagulant
properties, their fibrinolytic activity (3,4) and their ability
to contribute to thrombosis in vivo (5). The involvement
of EVs in the prothrombotic state in cancer is not limited
to their haemostatic phenotype. Indeed, EVs are known
to be a way of communication between cells and are
able to impact remote target cells’ phenotype (6). In this
context, it is anticipated that EVs target endothelial cells
and contribute to their activation and the disturbance
of their physiological anticoagulant properties.
This review aims at providing the latest evidence on the
contribution of EVs to the haemostatic balance in cancer
patients. A more specific discussion on their contributing
roles on the prothrombotic state in haematological malig-
nancies is also proposed.
Generated EVs in cancer
EVs are vesicles ranging from 0.03 to 1 mm generated by
almost all cell types, including endothelial cells, and they
play a role in intercellular communication (7). EVs are
heterogeneous and depending on their tissue of origin,
size or intracellular origin have been known by different
names, such as microparticles, oncosomes, microvesicles,
ectosomes, exosomes, and so on. Since the distinction
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between the different types of EVs is still challenging,
considering the various generation and isolation methods
used in the publications cited in this review, here we
chose to use only the generic term EVs (8). Cells com-
municate via several mechanisms: secreted molecules (9),
cell-to-cell direct contacts (10) and nanotubules forma-
tion (11). The communication by EVs is a more recently
discovered mechanism representing a major interest in
the scientific world. Cells in reaction to various stresses
and to apoptosis perform the EVs production. The
generated EVs exhibit surface proteins and can contain
cytoplasmic molecules, both originating from the produ-
cing cell (6). Thus, the analysis of surface proteins of
EVs can reveal the original cell. EVs are found in all
biological fluids such as saliva (12), urine (13), cere-
brospinal fluid (14) and blood (6).
Cancer cells are known to produce large amounts
of EVs contributing to the tumour microenvironment.
In addition, various cells in this microenvironment also
produce EVs in reaction to various stresses caused by the
tumour itself or the pharmacological treatment. To sup-
port this later hypothesis, a study highlighted an in vitro
chemotherapy-induced endothelial cell death triggering
a massive release of EVs (15). EVs produced during
tumourigenesis have been associated with a lot of cancer
features such as angiogenesis (16), inflammation (17),
chemoresistance (18), metastasis (16) and coagulation
(19). To support the roles of EVs on angiogenesis, Grange
et al. have demonstrated that EVs stimulate endothelial
cells to form neo-tubes and induce angiogenic factors
production by stromal cells (16). By interfering with im-
mune cells, EVs also contribute to create a favourable
inflammatory niche for tumour cells (17). EVs could also
transfer multidrug resistance from resistant cancer cells
to sensitive ones, partly due to miRNA transfer (18).
In addition, EVs enable the formation of a pre-metastatic
niche favourable to the implantation of a circulating
tumour cell (16,20). These characteristics are due to their
content in nucleic acids or in proteins but also to the
lipids and proteins present in their phospholipid mem-
brane. These various molecules enable EVs to interact
with target cells and modify their phenotype (6).
Contribution of EVs to the haemostatic
balance in cancer
The link between hypercoagulation and cancer is still an
interesting field of investigation even if several explana-
tions have already been discovered. Inflammatory state
linked to neoplasia, changes in protein metabolism and
venous stasis associated with cancer contribute to this
procoagulant phenotype (21). Nevertheless, a procoagulant
phenotype of tumour cells has also been highlighted
(22). First, an overexpression of tissue factor (TF) has
been observed on cancer cells surface (23). This major
member of coagulation cascade can activate this one by
binding to the serine protease FVII/VIIa to form an
activator complex. In this way, TF can promote throm-
bosis formation (24). In addition, tumour cells exhibit
higher levels of phosphatidylserine (PS) on their plasma
membrane compared to normal cells (25). These nega-
tively charged phospholipids form a catalytic surface for
the accumulation of coagulation cascade members (26)
and increase TF procoagulant activity (27). This procoa-
gulant phenotype of cancer cells may be responsible for
the formation of a thrombus close to the tumour. How-
ever, the occurrence of thrombosis far from the tumour
site has led to the hypothesis of another cause of throm-
bus formation in cancer. Indeed, EVs generated by tumour
cells also exhibit the same negatively charged phospho-
lipids and TF (3,28) and thus are thought to be partly
responsible for this distant thrombosis (19). In vivo mice
experiments demonstrated that cancer cellderived EVs
play a major role in thrombus formation (5). Neverthe-
less, some anticoagulant or fibrinolytic activities of endo-
thelial and cancer EVs have also been reported. This led
to the hypothesis that EVs reflect the haemostatic balance
of their original cell. In a normal healthy situation, there
would be an equilibrium between pro- and antithrom-
botic EVs. In cancer, this balance would be disturbed and
would favour prothrombotic EVs, thus increasing the
thrombotic risk (4). By analysing EVs from plasma of
healthy and cancer patients with a fluorescence-activated
cell sorting, Aharon and co-workers showed a decrease
in tissue factor pathway inhibitor (TFPI) expression on
EVs in cancer patients, while no significant difference
was observed for TF expression (29). TFPI inhibits TF’s
capacity to initiate blood coagulation and thus repre-
sents an antithrombotic protein (30). The increased ratio
of TF-positive EVs to TFPI-positive EVs (TF/TFPI)
observed in cancer patients would reflect the disturbed
balance towards pro-thrombotic EVs in these patients
(29). Heterogeneity in EVs’ phenotype is also observed
for PS expression. A study performed on blood from
normal healthy individuals by flow cytometry showed
that only 80% of platelet EVs express PS (31). Consistent
with these results, a recent cryo-Transmission Electron
Microscopy study concluded that about only 50% of
EVs are PS-positive (32). Considering the synergy be-
tween TF and PS exposure for TF activity (27), future
researches should analyse this heterogeneity in cancer
patients.
The ability of EVs to impact various target cells could
also disrupt the natural barriers against hypercoagulation
including the anticoagulant properties of blood vessels’
endothelium.
Contribution of EVs to vascular endothelial
cells activation
Because of the major role of blood vessels’ endothelium
as natural anticoagulant surface, tiny modifications of
Ce´line Bouvy et al.
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endothelial cells (named endothelial activation) could
contribute to thrombosis occurrence. Indeed, 3 mecha-
nisms of coagulation cascading inhibition by blood vessels’
endothelium have been highlighted. First, heparin-like
proteoglycans, located on endothelial cells surface, en-
hance the inhibition capacity of anti-thrombin and there-
fore contribute to thrombin inhibition (Fig. 1a) (33).
Second, endothelial cells exhibit the coagulation inhibitor
TFPI (30). TFPI binds to factor VIIa when this one
interacts with TF. This inhibition is strengthened by the
binding of factor Xa also neutralized by TFPI (Fig. 1b)
(30). Thirdly, the endothelium is where the protein C
anticoagulant pathway takes place. In this cascade,
thrombin procoagulant activity is inhibited by thrombo-
modulin (TM) enabling the activation of the protein C
by thrombin via the endothelial cell protein C receptor
(EPCR). The activated protein C (APC) detaches from
the EPCR and interacts with the protein S to inactivate
factor Va and VIIIa of the coagulation cascade (Fig. 1c)
(34,35).
In this context, various studies suggested vascular endo-
thelial activation in cancer (36) and the EVs generated
during tumourigenesis could contribute to this activation
and the disturbance of their haemostatic balance.
Induction of TF expression and decrease of
TFPI and TM
Various studies have assessed the potential impact of EVs
on endothelial cells’ anticoagulant activity. The first
highlighted effect was the induction of TF expression
by endothelial cells (Fig. 2c). In vitro studies showed an
increased antigenic expression of TF on endothelial cells
treated with leukocytes’ EVs (37,38) and tumour cells’
EVs, inducing an increased procoagulant activity of
endothelial cells (39). This increased surface expression
is probably due partly to a direct transfer of TF from EVs
surface to cellular cytoplasmic membrane (39). However,
several studies also highlighted an increased TF mRNA
expression after EVs treatment (37,38). These experi-
ments suggest a mechanism of action not limited to a
direct transfer of TF but comprising an impact on target
cells’ gene expression. EVs’ content in nucleic acids or
proteins could contribute to this increased gene expres-
sion in endothelial cells. A study suggests that leukocytes’
EVs could act on gene expression by the induction of
a sustained tyrosine phosphorylation of c-Jun NH2-
terminal kinase (JNK1) in endothelial cells (37). JNK1
phosphorylation is especially observed in cells under-
going stress conditions (40). JNK1 phosphorylation leads
to activator protein 1 (AP1) activation, a transcription fac-
tor complex known to induce TF transcription (41). One
in vivo study on TF-low mice also revealed this increa-
sed TF expression. Human tumour cells were trans-
planted to the mice presenting a very low TF expression.
Immunofluorescence analysis showed an important human
TF expression on blood vessels endothelial cells. These re-
sults argue in favour of a TF transfer from the xenograft
to the vascular endothelial cells via EVs (39).
The expression of anticoagulant proteins located at the
endothelial surface in normal conditions could also be
Fig. 1. Physiological anticoagulant characteristics of blood vessels on endothelial cells. (a) Heparin-like proteoglycans located on
endothelial cells’ surface enhance the inhibition capacity of anti-thrombin (AT). (b) Tissue factor pathway inhibitor (TFPI) in-
hibits tissue factor (TF) ability to initiate blood coagulation. TFPI actually binds to factor VIIa when this one interacts with TF.
This inhibition is strengthened by the binding of factor Xa also neutralized by TFPI. (c) The protein C anticoagulant pathway
takes place on endothelial cells surface. In this cascade, thrombin (T) procoagulant activity is inhibited by thrombomodulin (TM)
enabling the activation of the protein C (PC) by thrombin via the endothelial cell protein C receptor (EPCR). The activated protein
C (APC) detaches from the EPCR and interacts with the protein S (PS) to inactivate factor Va and VIIIa of the coagulation
cascade.
EVs and vascular haemostatic balance
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affected by EVs. Indeed, TFPI and TM expressions have
been shown to decrease in endothelial cells after EVs
treatment (Fig. 2c) (38).
Induction of endothelial apoptosis
Another impact of EVs on endothelium would be the
induction of endothelial cells apoptosis (Fig. 2d). This
has been shown in vitro with monocytic (38) or platelet
EVs (42). Apoptotic endothelial cells exhibit a procoa-
gulant phenotype due in part to the exposure of PS at
the plasma membrane during apoptosis process. These
exposed negative phospholipids represent a catalytic sur-
face for coagulation cascade. Apoptotic human umbilical
vein endothelial cells (HUVECs) also present a decreased
expression of coagulation inhibitors such as TM, heparan
sulphates and TFPI (43). Several mechanisms of endo-
thelial apoptosis induction by EVs have been proposed.
First, TF presented at EVs surface could play a role in
this cell death induction. A bifunctional role of TF was
proposed by Pradier et al. At low concentration, this
protein induces in vitro tube formation and confirms the
known pro-angiogenic role of TF. An apoptosis in-
duction was however highlighted at high concentration
of TF. Physiologically, these dose-dependent effects may
play a major role in tissue homeostasis. TF favours apop-
tosis of strongly damaged cells, while inducing reparation
of less injured tissues (44). No in vivo data suggests a
local sufficient concentration of EVs in cancer enabling
endothelial apoptosis induction. However, platelet EVs
have been shown to induce angiogenesis both in vitro and
in vivo (45). The underlying mechanism probably involves
not only TF.
Other EVs’ contents could induce endothelial apopto-
sis. Platelet EVs have been shown to contain miRNAs
and some of them are upregulated during inflammatory
response. In this context, Pan and co-workers showed that
miR-223 is transmitted to endothelial cells via platelet
EVs. miR-223 was able to increase in vitro advanced
glycation end products-induced apoptosis. This outcome
is probably due in part to the targeting of insulin-like
growth factor 1 receptor (IGF-1R) by this non-coding
RNA (42). Indeed, IGF-1R is known to be involved in
apoptosis protection of cancer cells (46).
Fig. 2. Impact of extracellular vesicles on endothelial cells’ anticoagulant properties. (a) In a physiologic state, blood vessels’
endothelium exhibits anticoagulant properties. (b) Extracellular vesicles generated during tumourigenesis could increase platelet
adhesion molecules’ expression by endothelial cells and thus, favour a procoagulant state of endothelium. (c) A decrease of tissue factor
pathway inhibitor and thrombomodulin expression could be induced by extracellular vesicles. Extracellular vesicles could also trigger
an increase in tissue factor on endothelial cells, contributing to a procoagulant phenotype. (d) Extracellular vesicles would induce
endothelial cells’ apoptosis. Apoptotic endothelial cells exhibit negatively charged phospholipids and produce extracellular vesicles both
contributing to a procoagulant phenotype of endothelial cells.
Ce´line Bouvy et al.
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Apoptosis being a mechanism of EVs production, this
process would represent an amplification loop in the
context of coagulation (Fig. 2d). Indeed, endothelial EVs
are also involved in cancer-associated procoagulant pheno-
type (15) and have been shown to trigger thrombin
generation in vitro and thrombus formation in vivo
(47). Another mechanism could also be involved in an
increased EVs production by endothelial cells. Pasquier
and co-workers recently proposed the hypothesis of an
induction of protein kinase B (PKB) phosphorylation
in endothelial cells triggered by breast and ovarian cancer
cell lines’ EVs. This activation of PKB would lead to
ADP-ribosylation factor 6 (Arf6) increased expression.
By acting on cytoskeleton, Arf6 would then induce EVs
budding (48).
Increased expression of platelet adhesion molecules
Activated endothelium has been shown to initiate plate-
lets rolling in vitro (49) and in vivo (50). This feature could
contribute to the establishment of a procoagulant state
by the adherence of platelets on activated endothelial cells.
In some particular pathophysiological conditions, the ex-
posure of subendothelial matrix by endothelium damage
is not necessary for platelet adhesion to vascular endo-
thelium. In cancer, the activation of endothelial cells by
EVs would also induce the adhesion of platelets and the
formation of platelet aggregates. Terrisse et al. observed
the formation of platelets strings on HUVECs after treat-
ment with endothelial, monocytic or platelet EVs (49).
This acquired pro-adhesive phenotype is probably due to
an increased expression of platelet adhesion molecules in
endothelial cells after EVs treatment (Fig. 2b).
Several adhesion molecules are implicated in platelet
endothelium interaction. First, P-selectin expressed on
activated endothelial cells by Weibel-Palade bodies’ exo-
cytosis, can mediate platelet adhesion via the P-selectin
glycoprotein ligand-1 (PSGL-1) expressed on platelets
(51,52). Experiments conducted on EVs-treated endothe-
lial cells have shown the importance of P-selectin for
platelet attachment to endothelium after EVs treatment.
In the same experiment, a member of the glycoprotein 1b
IXV, glycoprotein 1b (GP1b) has been highlighted for its
contribution in platelet adhesion because of the observed
reduced platelet strings formation after the addition of an
anti-GP1b antibody (49). This research group also demon-
strated the major role of von Willebrand factor (VWF) on
platelet adhesion after EVs treatment. An increased VWF
surface expression at endothelial cells membrane has been
highlighted after EVs treatment and the addition of an
anti-VWF antibody strongly reduces platelet rolling. The
induction mechanism of VWF surface expression by EVs
implicates a reactive oxygen species (ROS) accumulation in
endothelial cells. Indeed, endothelial and monocytic EVs
trigger ROS generation in endothelial cells in vitro (53,54).
The expression of VWF and the resulting platelet adhesion
was decreased by inhibition of ROS (49). The actual
interaction between GP1b, VWF and platelets remains to
be clarified. An indirect link between GP1b and platelets
via a stabilization of VWF strings at endothelial cells
surface by GP1b is the current hypothesis (55). However, a
direct binding of GP1b to a platelet receptor is not
excluded. This increased level of VWF at endothelial cell
surface after EVs treatment could impact on endothelial
EVs composition. Indeed, VWF has been detected on
endothelial EVs and would induce platelet aggregation in
vitro, thus contributing to a procoagulant state in cancer
patients (56).
The induction of intercellular adhesion molecule-1
(ICAM-1) in endothelial cells after platelet EVs treat-
ment has been observed in vitro (57). Even if ICAM-1
is well known for its ability to bind leukocytes during
inflammation and diapedesis process, this molecule is also
able to interact with platelets and would promote platelet
aggregation to endothelial cells (58). In this context,
ICAM-1 expression in endothelial cells after EVs stimu-
lation could promote platelet aggregation in vivo in blood
vessels and favour thrombosis occurrence.
Hypothesis supporting the role of EVs in
prothrombotic state in haematological
malignancies
At first, solid tumours were thought to induce more throm-
botic events than haematological malignancies (59).
However, comparable thrombotic rates between these
2 types of cancer have been reported (60). Furthermore,
new treatments with immunomodulatory drugs such as
thalidomide and the use of central vein catheter have
increased the incidence of thrombotic events in haema-
tological cancers. The use of oral contraceptives before
diagnosis was also highlighted as a risk factor (61).
The prevalence of thrombosis in haematological cancers
differs depending on the malignancy and ranges from
2 to 12% (59). Patients with haematological malignancies
have a 26-fold increased risk of developing thrombosis
compared to the general population (62). Incidence of
thrombosis in acute leukaemia ranges between 2 and 12%
in the literature (6365). Similar incidences have been
highlighted for other haematological malignancies. A
10% incidence of thrombotic events was described for
myeloma patients (66) and from 5 to 10% for lymphoma
patients (59,67).
Several processes would contribute to the procoagulant
phenotype observed in haematological cancers. The pro-
coagulant phenotype of tumour cells and the expression
changes of host cells due to a stressful microenvironment
are involved in the coagulopathy of haematological malig-
nancies as in cancer in general (68). A resistance to APC
was also highlighted in solid tumours (69) as in haema-
tological cancers (70). APC resistance is characterized by
a poor anticoagulant response of plasma after the addition
EVs and vascular haemostatic balance
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of APC. In a non-cancer situation, APC resistance is often
due to a factor V Leiden mutation (71). However, a
decreased level of protein S, the cofactor of APC and
a reduced level of TFPI in haematological cancers seem to
be more likely responsible for the resistance observed (70).
EVs have also been shown to contribute to this throm-
bosis occurrence in haematological cancers. A procoagu-
lant phenotype of leukaemic EVs has been highlighted
by Gheldof et al. in vitro. TF and PS expression by these
EVs was shown to be involved in this procoagulant
potential (3). A recent clinical study conducted on 7
patients suffering from acute myelocytic leukaemia seems
to correlate these results (72). A clinical study also
observed an increased EVsTF activity in multiple
myeloma (73). A potential involvement of EVs in a TM
resistance has also been suggested in a study analysing
plasma from patients suffering from myeloproliferative
neoplasms (MPN). Plasma from MPN patients presented
a higher procoagulant activity by thrombin generation
assay than plasma from healthy patients. By the addition
of TM to plasma, a lower inhibition of the thrombin gen-
eration was observed with plasma from MPN patients.
The filtration of plasma through a 0.22-mm filter en-
hanced the effect of TM on thrombin generation
suggesting an involvement of EVs in this observed TM
resistance (74).
Vascular endothelial activation probably contributes to
the procoagulant phenotype in haematological malig-
nancies. Indeed, some in vivo results suggest an endothe-
lium activation in haematological malignancies. Increased
levels of circulating P-selectin and VWF have been ob-
served in patients’ blood compared to controls and would
reflect this endothelial activation (75). A procoagulant
activity of endothelial cells after daunorubicin, doxoru-
bicin or epirubicin treatment has also been highlighted
(76) and an increased release of procoagulant endothelial
EVs was observed after daunorubicin treatment (77).
In this context, EVs generated during tumourigenesis
could contribute to this endothelium activation by the
previously described mechanisms. This new insight into
endothelial activation mechanism in cancer might be an
interesting field of investigation for the discovery of new
prophylactic treatments in haematological malignancies.
EVs might represent a new prophylactic target. Indeed,
thrombosis prophylaxis is still challenging due to an in-
creased bleeding risk of oncohaematological patients
that could suffer from thrombocytopenia for a prolonged
time (59). The American Society of Clinical Oncology
recommends the use of prophylaxis in cancer patients
undergoing surgical procedures or hospitalization. For
multiple myeloma patients, the use of low molecular
weight heparin or low-dose aspirin is recommended for
patients treated with antiangiogenesis agents combined
with chemotherapy and/or dexamethasone (78). For am-
bulatory patients, the lack of validated markers to define
high-risk patients of thrombotic events still hampers the
use of anticoagulants in these patients (59). In this con-
text, endothelial EVs might serve as biomarkers describing
endothelial activation that would contribute to procoa-
gulant phenotype. Soluble proteins produced by activated
endothelial cells could also have the same purpose. Mem-
bers of the selectin family such as E-selectin, specifically
expressed by endothelial cells, or members of the integrin
or adhesion molecules families represent potential new
biomarkers (79).
Conclusion
To sum up, EVs have been shown to contribute to the
procoagulant phenotype observed in cancer patients.
On one hand, they bear TF and PS that directly promote
thrombosis by acting on coagulation cascade. On the
other hand, they can target and activate endothelial vas-
cular cells becoming procoagulant in cancer. This new
insight into the mechanism of procoagulant phenotype
acquisition in cancer would be of particular interest
for haematological malignancies. Indeed, the prophylaxis
treatment to avoid thrombosis in oncohaematological
patients remains challenging due to the increased risk of
bleeding in these patients. Endothelial EVs might serve
as biomarkers of vascular endothelial status and would
help in identifying high-risk patients for thrombosis. EVs
might also represent new targets for prophylactic treat-
ment of haematological cancers by directly inhibiting
their procoagulant phenotype or by interfering with their
targeting of endothelial cells.
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